340 related articles for article (PubMed ID: 19303700)
1. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
[TBL] [Abstract][Full Text] [Related]
2. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells.
Chiang IT; Liu YC; Wang WH; Hsu FT; Chen HW; Lin WJ; Chang WY; Hwang JJ
In Vivo; 2012; 26(4):671-81. PubMed ID: 22773582
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.
Kuo TC; Lu HP; Chao CC
Biochem Pharmacol; 2011 Jul; 82(2):184-94. PubMed ID: 21549688
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
8. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
9. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
10. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
11. Fluoxetine Induces Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits ERK/NF-κB-Modulated Anti-Apoptotic and Invasive Potential in Hepatocellular Carcinoma Cells In Vitro.
Chen WT; Hsu FT; Liu YC; Chen CH; Hsu LC; Lin SS
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30754643
[TBL] [Abstract][Full Text] [Related]
12. Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells.
Chiao PJ; Na R; Niu J; Sclabas GM; Dong Q; Curley SA
Cancer; 2002 Oct; 95(8):1696-705. PubMed ID: 12365017
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
[TBL] [Abstract][Full Text] [Related]
14. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
[TBL] [Abstract][Full Text] [Related]
16. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
[TBL] [Abstract][Full Text] [Related]
17. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Fernando J; Sancho P; Fernández-Rodriguez CM; Lledó JL; Caja L; Campbell JS; Fausto N; Fabregat I
J Cell Physiol; 2012 Apr; 227(4):1319-25. PubMed ID: 21604268
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
